source
- Authors rebut mischaracterization of their 2023 Lancet Covid study in recent op-edThe authors of a 2023 Lancet analysis on the United States Covid response wrote to correct a recent First Opinion piece that they say misrepresented their work. While they welcome calls for additio…
- Moderna maintains 10% growth target despite Phase 3 norovirus missModerna’s norovirus vaccine failed in a Phase 3 trial, but the company still has faith in an ambitious revenue growth target thanks to ex-U.S. vaccine sales and a unanimous FDA adcomm win for mFLUS…BioSpace · 2h ago↗ source
- Sanofi CEO pledges deeper review of late-stage pipeline before Phase 3 moves